CELU · Celularity Inc
$0.74
+0.04 (+5.85%)
At close · Aug 18
Going-concern doubt
— flagged Apr 30, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our historical operating results indicatesubstantial doubt exists related to our ability to continue as a going concern.”View the 10-K filed Apr 30, 2026
Market Cap
$21.32M
Shares
28.95M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Adrian Kilcoyne | M.D., M.P.H., M.B.A. Former Executive Vice President and Chief Medical Officer | $1,238,065 |
| Robert J. Hariri | M.D., Ph.D. Chief Executive Officer | $1,234,342 |
| John R. Haines | Executive Vice President and Chief Administrative Officer | $815,815 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert J. Hariri | M.D., Ph.D. Chief Executive Officer | $5,242,529 |
| John R. Haines | Executive Vice President and Chief Administrative Officer | $2,503,571 |
| David C. Beers | Chief Financial Officer | $1,705,032 |
| Adrian Kilcoyne | M.D., M.P.H., M.B.A. Former Executive Vice President and Chief Medical Officer | $267,583 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert J. Hariri | M.D., Ph.D. Chief Executive Officer | $21,819,756 |
| Andrew L. Pecora | M.D., F.A.C.P. President | $9,050,997 |
| John R. Haines | Senior Executive Vice President, General Manager and Chief Administrative Officer | $4,026,127 |
| David C. Beers | Chief Financial Officer | $1,474,899 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert J. Hariri | M.D., Ph.D. Chief Executive Officer | $2,681,654 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Rick Gonzalez | Chief Commercial Officer | Terminated | 2026-08-07 |
| Vincent LeVien | member of the Company’s Board of Directors | Resigned | 2026-06-30 |
| Steven N. Gordon, Esq. | member of the Board | Appointed | 2026-06-25 |
| Steven N. Gordon, Esq. | Chief Operating and Administrative Officer | Appointed | 2026-06-25 |
| Rick Gonzalez | Chief Commercial Officer | Appointed | 2026-06-03 |
| Stephen A. Brigido | President, Degenerative Diseases | Resigned | 2026-04-21 |
| John Sprague | Acting Chief Financial Officer | Appointed | 2026-03-05 |
| Joseph DosSantos | interim CFO | Appointed | 2025-06-10 |
| David Beers | Chief Financial Officer | Terminated | 2025-06-10 |
| Vincent LeVien | Class II director | Appointed | 2025-06-06 |
| Dean Kehler | director | Resigned | 2025-05-16 |
| Adrian Kilcoyne, M.D., M.P.H., M.B.A. | Executive Vice President and Chief Medical Officer | Resigned | 2024-09-13 |
| Richard J. Berman | Class II director | Appointed | 2024-08-28 |
| Marc Mazur | Class III member of the Board of Directors | Resigned | 2024-08-05 |
| Robin L. Smith, MD | member of the board of directors | Resigned | 2023-12-29 |
| Lim Kok Thay | a Class II member of the board of directors of the Company | Resigned | 2023-09-19 |
| Geoffrey Shiu Fei Ling, M.D. | Class I director | Appointed | 2023-09-07 |
| Andrew C. von Eschenbach, M.D. | Class I member of the board of directors | Resigned | 2023-09-07 |
| John Sculley | Class III member of the board of directors | Resigned | 2023-08-04 |
| Bradley Glover | Executive Vice President and Chief Operating Officer and principal operating officer | Resigned | 2023-05-19 |
| Bradley Glover, Ph.D. | Executive Vice President and Chief Operating Officer | Appointed | 2022-10-06 |
| John R. Haines | Senior Executive Vice President, General Manager and Chief Administrative Officer | Appointed | 2022-10-06 |
| Andrew L. Pecora | President | Resigned | 2022-07-20 |
| Diane Parks | Class I director | Appointed | 2022-06-03 |
| Jay R. Bloom | Class I member of the board of directors | Resigned | 2022-06-03 |
Key facts
CIK
1752828
CUSIP
151190204
13F (30d)
39 filings
39 filers
Visit website
Investor relations